AbbVie To Acquire Apogee Therapeutics For $10.9 Billion In Largest Deal Since Allergan Acquisition

Tiger Newspress06-22 22:18

Global pharmaceutical giant AbbVie announced on Monday that it has entered into a definitive agreement to acquire clinical-stage biotech company Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, marking AbbVie’s largest acquisition since its $63 billion purchase of Allergan, the maker of Botox, in 2019.

Under the terms of the agreement, AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash, representing an equity value of roughly $10.9 billion. The offer reflects a premium of about 49% to Apogee’s closing price on June 18.

The announcement sent Apogee shares soaring nearly 47%, while AbbVie gained almost 5% in early trading. The transaction has been unanimously approved by the boards of directors of both companies and is expected to close in the third quarter of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment